VIDEO: Belzutifan plus cabozantinib potential treatment for advanced renal cell carcinoma
Click Here to Manage Email Alerts
MADRID —Tian Zhang, MD, discussed the positive results presented at ESMO Congress on use of belzutifan combined with cabozantinib for patients with advanced clear cell renal cell carcinoma.
The phase 2 LITESPARK-003 study looked at the HIF-2alpha inhibitor belzutifan (Welireg, Merck) combined with the VEGF receptor cabozantinib (Cabometyx, Exelixis) in patients with no prior systemic therapy for advanced renal cell carcinoma, and those who had received prior immunotherapy and two or more systemic regimens.
There was a “really nice objective response rate of around 70%” observed in the treatment-naive population and good responses in the pretreated population, according to Zhang, genitourinary oncologist at UT Southwestern Medical Center and member of the Kidney Cancer Association's Medical Steering Committee.
“There are multiple trials ongoing now that are combining belzutifan in the front-line setting and even earlier in the adjuvant setting. So, the belzutifan and cabozantinib data really set that up very well for further combination strategies,” Zhang said.
Reference:
- Choueiri TK, et al. Abstract LBA87. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Read more about
Click Here to Manage Email Alerts